Navigation Links
Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients

Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates... -- LONDON and SAN FRANCISCO, September 22, 2010 /PRNewswire-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Publishing & Information Services, Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Surveys, Polls and Research, Clinical Trials & Medical Discoveries Click to view news release full screen  

Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients


LONDON and SAN FRANCISCO, September 22, 2010 /PRNewswire-FirstCall/ --

- Phase II Study Published in the New England Journal of Medicine

AstraZeneca's (LSE: AZN) new oral syk inhibitor, fostamatinib (R788), recently in-licensed from Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), significantly improved outcomes of patients with rheumatoid arthritis (RA) who responded inadequately to ongoing treatment with methotrexate (MTX), according to phase II study data published in The New England Journal of Medicine today.

In the six-month phase IIb study completed by Rigel, known as TASKi2, 67% of patients taking fostamatinib 100mg twice daily achieved the primary efficacy endpoint (ACR 20)* at six months, which was significantly higher than placebo. Thirty-six percent of patients achieved an ACR 20 response after just one week. Speed of onset may be an important factor in RA because permanent joint damage can occur when the disease is active. The most common adverse events included diarrhea and upper respiratory infection.

"In this study, we saw a significant clinical benefit in this rheumatoid arthritis population and a manageable safety profile," said Mark C. Genovese, Division of Rheumatology, Stanford University, Palo Alto, CA. "Based on the data, further study of fostamatinib as an oral agent for the treatment of patients with rheumatoid arthritis is certainly warranted."

Patients in the study had active RA despite treatment with MTX alone, and were given either fostamatinib 100mg twice daily (bid), fostamatinib 150mg once daily (qd), or placebo. Significant clinical benefits were reported in both fostamatinib groups in the key efficacy endpoints of the American College of Rheumatology (ACR) patient assessment criteria and Disease Activity Score (DAS) 28** remission criteria.

After six months: - The ACR 20 response was achieved by significantly more patients in both the fostamatinib 100mg bid group and the fostamatinib 150mg qd group (67% and 57% respectively) than the placebo group (35%, p<0.001). - The ACR 50* response rates were 43%, 32% and 19% for the fostamatinib 100mg bid group, 150mg qd group and placebo group respectively (p<0.01). The ACR 70* response rates were 28%, 14% and 10% for the fostamatinib 100mg bid group, 150mg qd group and placebo group respectively (p<0.001 for fostamatinib 100mg bid, p=0.34 for fostamatinib 150 mg qd). - In addition, the DAS 28 remission rate was significantly higher in both the fostamatinib 100mg bid group and the fostamatinib 150mg qd group (31% and 21% respectively), compared to the placebo group (7%, p<0.01).

The published data indicates that the most common drug-related adverse events in the study were diarrhea (19% in 100mg bid group, 12% in the 150mg qd group and 3% in the placebo group), upper respiratory infection (15%, 7% and 7% respectively) and neutropenia (6%, 7% and 1% respectively). Hypertension (BP>140/90) occurred more frequently in fostamatinib treated patients than placebo (29% across both fostamatinib groups compared to 17% in placebo group) as had been previously reported. The hypertension generally occurred within the first few weeks of therapy and was responsive to conventional anti-hypertensive medications.

There were a similar proportion of patients who had at least one adverse event (AE) among the placebo group and the fostamatinib groups (65%). Ninety-four percent of eligible patients enrolled in an ongoing long-term open label extension study. The low rate of withdrawals is additional evidence that the adverse events were manageable in the patients studied.

AstraZeneca plans to commence the phase III clinical trial programme for fostamatinib shortly. The phase III programme, called OSKIRA (Oral Syk Inhibition in Rheumatoid Arthritis), is expected to begin in the second half of 2010.

* The ACR 20 response criteria is defined as greater than or equal to 20% improvement from baseline in both tender and swollen joints, and greater than or equal to 20% improvement in three of five measures: pain, acute phase reactant, physical function, patient and physician global assessment. ACR 50 and ACR 70 assess greater than or equal to 50% improvement and greater than or equal to 70% improvement in those areas respectively. ** DAS 28 is a measure of the activity of Rheumatoid Arthritis assessing 28 joint counts in the body

About Fostamatinib

Fostamatinib (previously referred to as R788), is the first oral syk inhibitor in development as a novel therapeutic approach for RA. It is thought to reversibly block signalling in multiple cell types involved in inflammation and tissue degradation in RA.

In February 2010, AstraZeneca and Rigel Pharmaceuticals announced a worldwide license agreement whereby AstraZeneca will develop and commercialise fostamatinib.

About RA

Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disease, which causes damage to the joints and other organs, affecting approximately 1 in 100 people. It is a major cause of disability and is also associated with reduced life expectancy, especially if not adequately treated.

About the TASKi2 Study Design

TASKi2 was a 6 month, multi-center, randomized, double-blind, placebo controlled, parallel dose clinical trial involving 457 RA patients in the U.S., Latin America and Europe who had active RA despite treatment with MTX alone. Approximately 1/3 of the patients (n=152) studied received 100mg of fostamatinib orally bid. Another third received 150mg of the study drug qd and the final third were given placebo to be taken orally bid or qd (total placebo n=153). Throughout the study all patients continued to receive their stable dose of MTX.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit:

About Rigel

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune, muscle and metabolic diseases. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib (R788), an oral syk inhibitor that is expected to enter phase III clinical trials for rheumatoid arthritis in 2010, and R343, an inhaled syk inhibitor that is in clinical trials for asthma.

Rigel Forward-Looking Statements

This press release contains "forward-looking" statements, including, without limitation, statements related to plans to pursue further clinical development of R788 (fostamatinib), including the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "estimate," "anticipate" and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based upon Rigel's current expectations and involve risks and uncertainties. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including, without limitation, risks associated with the timing and success of clinical trials and other risks detailed from time to time in Rigel's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2010. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
2. More Evidence Published That Epidemics of Childhood Obesity, Type 2 Diabetes and Metabolic Syndrome are Linked to Immunization
3. Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
4. Wound Management Technologies, Inc. Announces a Published Case Study
5. Technique for Creating Authentic Rat Embryonic Stem Cells Published in Cell
6. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
7. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
8. Universal Bioenergy, Inc. Expressly Disclaims Any Responsibility for the Content, Accuracy of Information, and Quality of Information Regarding Universal Published by Any Third-Party and Being Disseminated on the Internet
9. International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
10. Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth
11. Life sticks: UC San Diego bioengineers sticky insights published in journal Science
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing ... Aerospace Professionals (OPBAP) has been formalized with the signing of a Memorandum of ... with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, ...
(Date:11/25/2015)... , November 25, 2015 ... Research Report is a professional and in-depth study ...      (Logo: ) , ... of the industry including definitions, classifications, applications and ... provided for the international markets including development trends, ...
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
Breaking Biology Technology:
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Sensors - Technology and Patent Infringement Risk Analysis" ... --> Fingerprint sensors using capacitive technology ... fingerprint sensor vendor Idex forecasts an increase of 360% ... devices and of the fingerprint sensor market between 2014 ...
(Date:11/20/2015)... Connecticut , November 20, 2015 ... authentication company focused on the growing mobile commerce market ... CEO, Gino Pereira , was recently interviewed on ... interview will air on this weekend on Bloomberg ... Latin America . --> NXTD ) ("NXT-ID" ...
(Date:11/19/2015)... , Nov. 19, 2015  Based on its in-depth ... Sullivan recognizes BIO-key with the 2015 Global Frost & ... Frost & Sullivan presents this award to the company ... to the needs of the market it serves. The ... meets and expands on customer base demands, the overall ...
Breaking Biology News(10 mins):